Spero Therapeutics

SPRO · NASDAQ

$1.22+$0.10 (+8.93%)TodayMarket closed · Oct 20, 7:40 PM ET

Prev close $1.12

SPRO analyst rating

BuyConsensus of 1 analyst over the last 12 months. 100% rate it a buy.

Strong buy0
Buy1
Hold0
Underperform0
Sell0

12-month price target · 4 analysts

Average $5.10 (+318.0% upside)

Low: $4.04
Now: $1.22
High: $6.30

Upgrades and downgrades

The latest rating actions, newest first

SPRO analyst upgrades, downgrades and rating actions
Firm	Date	Action	Rating	Price target	Hit rate
HC Wainwright & Co.	Sep 14, 2026	Maintains	Buy	$5.00 → $6.00	43%

The case for and against

Updated May 22, 2025

Bull case

Spero Therapeutics Inc is making significant progress in its clinical programs, notably with the FDA's clearance of its IND application for a Phase 2 trial targeting hospital-acquired or ventilator-associated bacterial pneumonia, suggesting a strong regulatory outlook for its product candidates. The ongoing PIVOT-PO Phase 3 trial for tebipenem HBr is on track, aiming to demonstrate efficacy against complicated urinary tract infections, and compelling results could pave the way for approval and commercial use. Additionally, Spero's collaboration with GlaxoSmithKline presents considerable financial upside, with potential milestone and royalty payments totaling up to $400 million, enhancing the company's revenue prospects as it advances its antibiotic pipeline.

Bear case

Spero Therapeutics Inc. reported a net loss of $0.32 per share for the third quarter of 2024, with forecasts indicating a worsening financial outlook with a projected net loss of $1.23 per share for the full year 2024 and $0.84 per share for 2025. Compounding these concerns are substantial risks including the potential failure to secure U.S. approval for key product SPR994, challenges in commercializing this product, setbacks with other candidates like SPR206, and the potential for medium-term dilution risks. Additionally, the company has recognized a significant impairment of long-term assets amounting to $5.3 million, further highlighting its financial vulnerabilities.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.